Eterna Therapeutics Inc (NASDAQ: ERNA)’s stock price has gone decline by -8.08 in comparison to its previous close of 0.99, however, the company has experienced a -17.33% decrease in its stock price over the last five trading days. globenewswire.com reported 2024-10-17 that CAMBRIDGE, Mass., Oct. 17, 2024 (GLOBE NEWSWIRE) — Eterna Therapeutics Inc. (Nasdaq: ERNA) (“Eterna” or the “Company”) and Factor Bioscience Limited (“Factor”) today announced an exclusive license and collaboration agreement aimed at accelerating the development of advanced cell therapy candidates for oncology, rare diseases, and autoimmune disorders. Under the terms of the agreement, Eterna has secured a worldwide, exclusive, non-transferable, royalty-bearing license, with the right to grant sublicenses, to develop and market certain induced pluripotent stem cell (iPSC)-based cell therapy products (in particular iPSC derived mesenchymal stem cells (iMSC) that are engineered to express certain cytokines) utilizing Factor’s cell reprogramming and gene-editing technologies, patents, and know-how. The agreement positions both companies with the potential to accelerate the development of advanced cell therapies in the oncology, rare disease, and autoimmune fields.
Is It Worth Investing in Eterna Therapeutics Inc (NASDAQ: ERNA) Right Now?
The stock has a 36-month beta value of 4.45. Opinions on the stock are mixed, with 0 analysts rating it as a “buy,” 0 as “overweight,” 1 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for ERNA is 2.79M, and at present, short sellers hold a 1.95% of that float. On October 23, 2024, the average trading volume of ERNA was 26.16K shares.
ERNA’s Market Performance
ERNA’s stock has seen a -17.33% decrease for the week, with a -25.41% drop in the past month and a -52.60% fall in the past quarter. The volatility ratio for the week is 13.18%, and the volatility levels for the past 30 days are at 15.80% for Eterna Therapeutics Inc The simple moving average for the past 20 days is -13.22% for ERNA’s stock, with a -48.93% simple moving average for the past 200 days.
ERNA Trading at -34.52% from the 50-Day Moving Average
After a stumble in the market that brought ERNA to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -65.33% of loss for the given period.
Volatility was left at 15.80%, however, over the last 30 days, the volatility rate increased by 13.18%, as shares sank -19.47% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -51.08% lower at present.
During the last 5 trading sessions, ERNA fell by -17.33%, which changed the moving average for the period of 200-days by -53.57% in comparison to the 20-day moving average, which settled at $1.0486. In addition, Eterna Therapeutics Inc saw -49.30% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for ERNA
Current profitability levels for the company are sitting at:
- -135.73 for the present operating margin
- -10.99 for the gross margin
The net margin for Eterna Therapeutics Inc stands at -147.65. The total capital return value is set at -0.6. Equity return is now at value -1154.18, with -51.20 for asset returns.
Based on Eterna Therapeutics Inc (ERNA), the company’s capital structure generated 2.84 points at debt to capital in total, while cash flow to debt ratio is standing at -1.25. The debt to equity ratio resting at -1.54. The interest coverage ratio of the stock is -10.55.
Currently, EBITDA for the company is -19.55 million with net debt to EBITDA at -2.35. When we switch over and look at the enterprise to sales, we see a ratio of 318.16. The receivables turnover for the company is 0.71for trailing twelve months and the total asset turnover is 0.0. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.37.
Conclusion
To sum up, Eterna Therapeutics Inc (ERNA) has seen a bad performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
